CG Oncology (NASDAQ:CGON) Trading Down 0.9%

CG Oncology, Inc. (NASDAQ:CGON - Get Free Report)'s stock price was down 0.9% on Thursday . The stock traded as low as $29.26 and last traded at $30.25. Approximately 408,077 shares were traded during trading, a decline of 39% from the average daily volume of 672,452 shares. The stock had previously closed at $30.52.Analysts Set New Price TargetsA number of equities research analysts recently issued reports on CGON shares. The Goldman Sachs Group raised shares of CG Oncology from a "neutral" rating to a "buy" rating and lifted their price target for the company from $43.00 to $50.00 in a research note on Monday, May 13th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $75.00 target price on shares of CG Oncology in a research note on Thursday, May 2nd. Finally, HC Wainwright reiterated a "buy" rating and set a $75.00 price target on shares of CG Oncology in a report on Tuesday, May 28th.Read Our Latest Report on CG OncologyCG Oncology Trading Down 0.9 %The stock's fifty day moving average price is $33.57. CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.01). The company had revenue of $0.53 million for the quarter. As a group, analysts forecast that CG Oncology, Inc. will post -1.71 EPS for the current year. Hedge Funds Weigh In On CG OncologyInstitutional investors and hedge funds have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. acquired a new position in shares of CG Oncology during the first quarter worth about $102,000. California State Teachers Retirement System acquired a new position in CG Oncology in the first quarter valued at approximately $103,000. BNP Paribas Financial Markets acquired a new position in CG Oncology in the first quarter valued at approximately $492,000. Capstone Investment Advisors LLC acquired a new position in CG Oncology in the first quarter valued at approximately $806,000. Finally, Blackstone Inc. acquired a new position in CG Oncology in the first quarter valued at approximately $1,098,000. 26.56% of the stock is owned by institutional investors and hedge funds. CG Oncology Company Profile (Get Free Report)CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.Featured StoriesFive stocks we like better than CG OncologyRussell 2000 Index, How Investors Use it For Profitable TradingBlackBerry Stock: Strong Earnings, Profitability Challenges AheadHow Can Retail Investors Trade the Toronto Stock Exchange (TSX)?Progress Software Stock Back in the Green After Beating ForecastsHow to Use the MarketBeat Excel Dividend CalculatorGoldman Sachs Raises Stock Target for Affirm: Key InsightsThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.→ Elon’s Next IPO Could be Bigger than Tesla (From Paradigm Press) (Ad)Should you invest $1,000 in CG Oncology right now?Before you consider CG Oncology, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.While CG Oncology currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here